Full year 2020 financial and operational results. Stocks with a zacks rank of 1, 2, or 3, with a positive esp were shown to positively surprise 70% of.
(lpcn) stock quote, history, news and other vital information to help you with your stock trading and investing.
Lpcn stock forecast zacks. Lipocine (nasdaq:lpcn) announced its earnings results on wednesday. Their forecasts range from $3.00 to $3.50. After multiple extensions from the august 2020 target action date, the fda granted tentative approval of lipocine’s (nasdaq:lpcn) tlando on december 8th.
Salt lake city (ap) _ lipocine inc. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping the zacks consensus estimate of ($0.04) by $0.01, marketwatch earnings reports. Fda grants tentative approval to tlando.
Lpcn investment & stock information. This suggests a possible upside of 210.5% from the stock's current price. Tlando met all required quality, safety and efficacy standards necessary for.
Lipocine last released its quarterly earnings results on november 10th, 2021. Lipocine has generated ($0.21) earnings per share over the last year ( ($0.21) diluted earnings per share). Nasdaq:lpcn traded up $0.01 on friday, hitting $1.19.
Get the latest lipocine inc. Find the latest lipocine inc. According to the issued ratings of 3 analysts in the last year, the consensus rating for lipocine stock is buy based on the current 3 buy ratings for lpcn.
Stock screener for investors and traders, financial visualizations. The specialty pharmaceutical company reported ($0.03) eps for the quarter, beating the consensus estimate of ($0.04) by $0.01. Each analyst's rating is normalized to a standardized rating.
Lipocine announces third quarter 2020 financial. Read the full lpcn research report. On lpcn's analyst rating history.
The company reported zero revenues and a net loss per. Analyst price target for lpcn i we calculate consensus analyst ratings for stocks using the most recent rating from each wall street analyst that has rated a stock within the last twelve months. Read the full lpcn research report.
307,096 shares of the companys stock were. (lpcn) on wednesday reported a loss of $3.1 million in its third quarter. On average, they anticipate lipocine's share price to reach $3.17 in the next twelve months.
